The third CIIE will open on November 5. Under the Coronavirus (COVID-19) epidemic, the highlights of this year's CIIE are undoubtedly the medical exhibition area and the public health and epidemic prevention area. Dräger Medical, the German critical medical equipment supplier that participated in the CIIE for the third time, will be exhibiting in two exhibition areas this year.
At the height of the Coronavirus (COVID-19) epidemic in China, Dräger reached out to China. Today, despite the effective control of the epidemic in China, ventilators and other critically ill treatment-related medical equipment products still face an unprecedented demand gap.
Serious medical equipment gap
In an interview with Hay Think a few days ago, an executive from Dräger Greater China said that Dräger is moving more of its ventilator product lines to China, establishing a local supply chain, and is expected to export to the entire Asia-Pacific region in the future.
"After the Coronavirus (COVID-19) epidemic, China is paying more and more attention to critical care medicine." Shen Lixin, Sales Director of Dräger Medical Greater China, said, "The proportion of ICU/beds in developed countries such as Japan, Germany, and the United States Basically, it is above 15%, but according to the proportion, it may only be about 2%. The gap is serious. We hope to at least double the proportion of ICU/beds in China and reach more than 5% in the future."
Shen Lixin believes that the degree of development of critical care medicine is an important measure of the level of medical modernization in hospitals, including multinational medical device companies and Chinese local medical device manufacturers that are developing related equipment, but currently multinational companies are clearly dominant in the market.
According to statistics in 2019, Dräger's Chinese market share in the field of anesthesia machines accounts for about 40%, and the ventilator market share also accounts for about one-third. "We know that China is advocating the development of high-end manufacturing, and Dräger is also following this trend. When we talk about'decentralization', we hope that more high-end products can be produced in China." Shen Lixin told CBN The reporter said, "This has two advantages, one is to shorten the delivery period, and the other is to reduce costs."
He said that in the past, almost all of Dräger's production was in Germany, but later discovered that the market demand forecast could not be completely accurate, which would make the supply and delivery period uncertain, and the development of many products could not reflect local demand.
To this end, Dräger's first localized ventilator will be officially put into production next year. "The Shanghai factory will radiate the entire Asia-Pacific region." Shen Lixin said, "In this way, logistics costs can be reduced, and it can be more adapted to the needs of localized customers, and design some products that meet the characteristics of Asians."
Dong Guangcheng, Marketing Director of Dräger Greater China, said that after years of accumulation in the Chinese market, Dräger has cultivated a considerable number of local production suppliers. In the future, it is expected that more Chinese-made parts will be exported to Europe and other places, making the world The market can enjoy the advantages of China's supply chain.